4-hydroxyphenylpyruvic acid has been researched along with Alcaptonuria in 3 studies
4-hydroxyphenylpyruvic acid: RN given refers to parent cpd
4-hydroxyphenylpyruvic acid : A 2-oxo monocarboxylic acid that is pyruvic acid in which one of the methyl hydrogens is substituted by a 4-hydroxyphenyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We have assessed the effect of elevated concentrations of hydroxyphenylpyruvic acid (HPPA), hydroxyphenyllactic acid (HPLA) and tyrosine, on a range of chemistry tests in serum and urine to explore the potential for chemical interference on routine laboratory analyses in patients with alkaptonuria (AKU) treated with nitisinone and similarly implications for patients with hereditary tyrosinemia type 1 (HT-1)." | 7.91 | Interference of hydroxyphenylpyruvic acid, hydroxyphenyllactic acid and tyrosine on routine serum and urine clinical chemistry assays; implications for biochemical monitoring of patients with alkaptonuria treated with nitisinone. ( Curtis, SL; Gallagher, JA; Milan, AM; Norman, BP; Olsson, B; Ranganath, LR; Roberts, NB, 2019) |
| "We have assessed the effect of elevated concentrations of hydroxyphenylpyruvic acid (HPPA), hydroxyphenyllactic acid (HPLA) and tyrosine, on a range of chemistry tests in serum and urine to explore the potential for chemical interference on routine laboratory analyses in patients with alkaptonuria (AKU) treated with nitisinone and similarly implications for patients with hereditary tyrosinemia type 1 (HT-1)." | 3.91 | Interference of hydroxyphenylpyruvic acid, hydroxyphenyllactic acid and tyrosine on routine serum and urine clinical chemistry assays; implications for biochemical monitoring of patients with alkaptonuria treated with nitisinone. ( Curtis, SL; Gallagher, JA; Milan, AM; Norman, BP; Olsson, B; Ranganath, LR; Roberts, NB, 2019) |
| "The drug nitisinone (NTBC) is used to treat tyrosinemia type I, and more recently has been also used for the treatment of another disorder of tyrosine metabolism, alkaptonuria." | 3.81 | Perturbations of tyrosine metabolism promote the indolepyruvate pathway via tryptophan in host and microbiome. ( Barshop, BA; Gangoiti, JA; Gertsman, I; Nyhan, WL, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Curtis, SL | 1 |
| Norman, BP | 1 |
| Milan, AM | 1 |
| Gallagher, JA | 1 |
| Olsson, B | 1 |
| Ranganath, LR | 1 |
| Roberts, NB | 1 |
| Gertsman, I | 1 |
| Gangoiti, JA | 1 |
| Nyhan, WL | 1 |
| Barshop, BA | 1 |
| Nordlinger, BM | 1 |
| Fulenwider, JT | 1 |
| Faraj, BA | 1 |
| Bethel, RA | 1 |
| Rudman, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Nitisinone (NTBC) In Different Age Groups Of Patients With Alkaptonuria[NCT01390077] | Phase 2/Phase 3 | 8 participants (Actual) | Interventional | 2011-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Urine homogentisic acid (umol/mmol creatinine) (NCT01390077)
Timeframe: 3-6 months
| Intervention | uM (Mean) |
|---|---|
| HGA, Baseline | 1425.9 |
| HGA, 2 mg/d Nitisinone | 113.1 |
| HGA, 4 mg Nitisinone | 34.0 |
Plasma tyrosine (uM) (NCT01390077)
Timeframe: 3-6 months
| Intervention | uM (Mean) |
|---|---|
| Tyrosine, Baseline | 53.1 |
| Tyrosine, 2 mg/d Nitisinone | 668.7 |
| Tyrosine, 4 mg Nitisinone | 703.7 |
3 other studies available for 4-hydroxyphenylpyruvic acid and Alcaptonuria
| Article | Year |
|---|---|
Interference of hydroxyphenylpyruvic acid, hydroxyphenyllactic acid and tyrosine on routine serum and urine clinical chemistry assays; implications for biochemical monitoring of patients with alkaptonuria treated with nitisinone.
Topics: 4-Hydroxyphenylpyruvate Dioxygenase; Alkaptonuria; Cyclohexanones; Enzyme Inhibitors; Humans; Nitrob | 2019 |
Perturbations of tyrosine metabolism promote the indolepyruvate pathway via tryptophan in host and microbiome.
Topics: Aldehydes; Alkaptonuria; Cell Line, Tumor; Cyclohexanones; Gastrointestinal Microbiome; Humans; Indo | 2015 |
Tyrosine metabolism in cirrhosis: acquired alkaptonuria.
Topics: Alkaptonuria; Homogentisic Acid; Humans; Liver Cirrhosis; Liver Function Tests; Phenylpyruvic Acids; | 1978 |